PMC3671292_01
Left sided T1aN0M0 vocal cord carcinoma under surgical microscope.
CRIM.PULMONOLOGY2013-308092.001.jpg
PMC3671292_01_CRIM.PULMONOLOGY2013-308092.001.jpg
fig1
Within a year her voice turned increasingly hoarse and a second larynx carcinoma on the opposite vocal cord was discovered (Figure 1).
HRCT of the thorax after discontinuation of infliximab showing increased consolidation and nodular abnormalities.
CRIM.PULMONOLOGY2013-308092.002.jpg
PMC3671292_01_CRIM.PULMONOLOGY2013-308092.002.jpg
fig2
Unfortunately, half a year after infliximab discontinuation the small fiber neuropathy and pulmonary symptoms returned as shown on High Resolution CT of the chest (Figure 2) and on 18-FDG-PET scan which revealed extensive systemic reactivation of sarcoidosis (Figure 3).
18F-FDG-PET scan monitoring sarcoidosis activity level. In the left frame is shown the 18F-FDG-PET scan during treatment with infliximab and in the right frame the 18F-FDG-PET scan after discontinuation of infliximab revealing reactivation of sarcoidosis as black spots in lungs and lymph nodes.
CRIM.PULMONOLOGY2013-308092.003.jpg
PMC3671292_01_CRIM.PULMONOLOGY2013-308092.003.jpg
fig3
Unfortunately, half a year after infliximab discontinuation the small fiber neuropathy and pulmonary symptoms returned as shown on High Resolution CT of the chest (Figure 2) and on 18-FDG-PET scan which revealed extensive systemic reactivation of sarcoidosis (Figure 3).